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Epidemiological overview
of multidimensional chromosomal
and genome toxicity of cannabis
exposure in congenital anomalies
and cancer development
Albert Stuart Reece1,2* & Gary Kenneth Hulse1,2
Cannabis and cannabinoids are implicated in multiple genotoxic, epigenotoxic and chromosomal-toxic
mechanisms and interact with several morphogenic pathways, likely underpinning previous reports
of links between cannabis and congenital anomalies and heritable tumours. However the effects of
cannabinoid genotoxicity have not been assessed on whole populations and formal consideration
of effects as a broadly acting genotoxin remain unexplored. Our study addressed these knowledge
gaps in USA datasets. Cancer data from CDC, drug exposure data from National Survey of Drug
Use and Health 2003–2017 and congenital anomaly data from National Birth Defects Prevention
Network were used. We show that cannabis, THC cannabigerol and cannabichromene exposure
fulfill causal criteria towards first Principal Components of both: (A) Down syndrome, Trisomies 18
and 13, Turner syndrome, Deletion 22q11.2, and (B) thyroid, liver, breast and pancreatic cancers and
acute myeloid leukaemia, have mostly medium to large effect sizes, are robust to adjustment for
ethnicity, other drugs and income in inverse probability-weighted models, show prominent non-linear
effects, have 55/56 e-Values > 1.25, and are exacerbated by cannabis liberalization (P = 9.67 × 10–43,
2.66 × 10–15). The results confirm experimental studies showing that cannabinoids are an important
cause of community-wide genotoxicity impacting both birth defect and cancer epidemiology at the
chromosomal hundred-megabase level.
Cannabinoid-induced genotoxicity was first demonstrated by researchers in the 1960’s who showed multiple
congenital defects developing in prenatally exposed a nimals1–3, cannabinoid-induced micronucleus formation
from chromosomal mis-segregation errors and mitotic spindle disruption4, ring and chain chromosomal malformations in sperm5, nuclear blebbing and bridging of oocytes and lymphocytes during cytokinesis6,7 and direct
and indirect multimodal mitochondrial toxicities with downstream direct and indirect epigenetic e ffects4,8–12.
It has long been known that cannabinoids reduce histone formation and protamine substitution and synthesis
resulting in a more open chromosomal conformation which is more subject to mutagenicity and is also prooncogenic as more genes are available for t ranscription13–18. Cannabis has a large epigenetic footprint with major
alterations of DNA methylation, a change inheritable to subsequent generations in both mice and m
 an9,19–26.
An elegant and incisive molecular dissection of the cannabidiol-related genotoxic mechanisms was recently
published by the Parnell group which indicated that cannabidiol-hedgehog signalling and cannabinoid receptor type 1 (CB1R)—smoothened receptor heterodimerization was a key molecular mediator of developmental
malformations including orofacial cleft palate and lip deformities, exencephaly and microphthalmia/anophthalmia in mice and z ebrafish27. These authors also noted that since the hedgehog pathway is a key developmental
mechanism also implicated in many oncogenic pathways it could also be expected to implicated in the growth
and promotion of several cancers. This important predictive hypothesis has not been tested epidemiologically to
our knowledge. If confirmed it would clearly carry major public health and regulatory implications as it seems
very evident that the genotoxicity of many cannabinoids is not well appreciated currently in either lay or professional circles. Moreover promiscuous heterodimerization of the CB1R with many other G-protein receptors has
been reported including notch and C
 BR228, delta29 and mu30 opioid receptors, angiotensin I I31, serotonin 2A
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receptors32, GPR5533, orexin34, dopamine type 2A35 and adenosine 2A36. Heterodimerization of the CB1R changes
its downstream interactions with G-protein transduction coupling machinery and can change the polarity of
signalling from inhibition to activation27.
Presumptive evidence for cannabinoid-induced genotoxicity was first demonstrated in human populations
in Hawaii with the 2007 documentation of elevated rates of Down syndrome in infants prenatally exposed to
cannabis but not to other drugs, with OR 5.26 (95% CI 1.08–15.46)37. This finding has since been confirmed
in Colorado and A
 ustralia8,38 and by studies of US d
 ata39. Indeed a dramatic rise from the fourth to the fifth
quintiles of cannabis use amongst US states was recently reported for 34 congenital anomalies of birth including prominently cardiovascular and central nervous system disorders, orofacial clefts, limb reductions and the
chromosomal disorders Down syndrome, Trisomy 13, Turner syndrome and Deletion 22q11.239.
Testicular cancer, with its ubiquitous chromosome 12 a nomalies40–42, has been linked with parental cannabis
exposure in all four studies to examine this relationship43–46.
Together this list makes an impressive assemblage of the human genome. Chromosomes 12, 13, 18, 21, and
X are each 133, 114, 80, 48 and 153 megabases (MB) in length so together they comprise 528 MB (16.7%) of the
human genome which is in total about 3000 MB in length. This substantial list also leaves open the possibility
that cannabis may be generally toxic to human chromosomes including the possibility that damage related to
other chromosomes is filtered out by in utero foetal loss contributing to the lower fecundity and higher miscarriage rates known to occur amongst human women who consume cannabis47,48.
Cannabis use in parents has previously been linked with non-lymphoblastic leukaemia, several pediatric
sarcomas49–51 and in a recent causal inference report, with the rising rate of pediatric cancers across USA since
197052. This latter is important as it presents presumptive clinical evidence of intergenerational inheritance of
oncogenic mutagenicity and t eratogenicity53,54.
Whilst the relationships between cannabinoids and various morbidities are increasingly being studied, it
seemed timely to review the epidemiological evidence linking cannabinoid-induced genotoxicity to clinical
phenomenology at the epidemiological level using US space–time denominated drug and disorder data which
is the perhaps the most complete dataset globally using standard epidemiological tools. The objective here is to
provide in overview form an increased understanding of the implications of cannabinoid induced genotoxicity,
areas not well understood by medical or public health practitioners or in the general community.
Principal Components (PC) analysis is a classical statistical technique which quantifies the dominant trends
in a cloud of data points and allows several variables to be combined at once thereby allowing significant dimension reduction and streamlining of data analysis across multiple variables.
The central hypothesis to be investigated was whether there was a relationship between cannabis use and
Principal Components (PC’s) of the congenital anomalies Down syndrome, Trisomy 18 (Edwards syndrome),
Trisomy 13 (Patau’s syndrome), Turner syndrome, Deletion 22q11.2 (Di George syndrome), and selected cancers
namely thyroid, liver, breast and pancreatic cancers and acute myeloid leukaemia, and whether the association
fulfilled formal quantitative criteria of causality. The present study was intended to be an overview and introduction to the potentially broad impacts of cannabinoid genotoxicity across the chromosomal complement and was
useful to introduce the concept of large-scale genetic damage. Rather than considering morbidities separately
it was felt that additional insights could be gained by considering these syndromes together particularly with
regard to their impacts across the chromosomal landscape. This is not of course to suggest that detailed studies
on each pathology mentioned should not be conducted. And indeed for many of these issues we are doing just
this at the time of writing. However it was felt that much could be gained by the “wide-angled lens approach” in
parallel with detailed spatiotemporal and causal inference epidemiological analyses.
Our concerns in relation to cannabis and cannabinoids were heightened by the recent demonstration from
SAMHSA that cannabis use alone has risen across this period whilst the use of tobacco and alcohol use disorder
have declined55–57 and by the demonstration that the rate of daily or near daily cannabis consumption in USA
has recently doubled again based on SAMHSA d
 ata58. The rates of opioid use in household surveys has generally
declined and the rate of cocaine use has been consistently low level.
The emerging picture is in fact very concerning and indeed the very antithesis of the supposedly “soft drug
image” with which cannabis is invariably associated in popular culture. Epidemiological data implicates several
cannabinoids including cannabigerol, cannabinol and cannabichromene in addition to tetrahydrocannabinol
(THC). Public health concerns are heightened by the major theme coming through much cannabinoid genotoxicity and cell biology of an exponential dose–response r elationship14,26,59–61 which appears to have serious impacts
in environments where cannabis use is allowed to increase—with major multigenerational and transgenerational
implications.

Results

Cancer data was downloaded for the fifty US states from 2001 to 2017 from the SEER r egistry62. Congenital birth
anomaly data was taken from NBDPN CDC annual reports63. It was adjusted to include estimates of early termination of pregnancy for anomaly (ETOPFA) taken from the published l iterature64–66. These datasets were matched
with drug use data from NSDUH at SAMHSA for the period 2003–201767 so that the fifteen years 2003–2017
became the period of analysis. There were therefore 750 datapoints for analysis. This data was supplemented by
income and ethnicity data from US census bureau and cannabinoid concentration data from D
 EA68–70.
Cannabis use quintiles were calculated for each year. The mean percentage rates of cannabis use are shown
in Supplementary Table 1.
Four Principal Components (PC’s) were constructed in the domains of congenital anomaly (CA) rates (CAR),
ETOPFACAR’s, cannabinoid exposure and the five cancers of interest. Details of the composition of the PC’s are
shown in Supplementary Tables 2–5.
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Figure 1.  Raw congenital anomaly and cancer incidence data over time, by pathology type. (Created in
R-Studio version 1.3.1093 using ggplot version 3.3.2).
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Figure 2.  ETOPFA-corrected congenital anomaly and cancer incidence data as a function of THC exposure, by
pathology type. (Created in R-Studio version 1.3.1093 using ggplot2 version 3.3.2).
Figures 1 and 2 show the rate of the various disorders over time for raw data and after ETOPFA-adjustment
respectively. In all cases the dependent variables listed were rising with time (Fig. 1). ETOPFA adjustment for the
congenital anomalies has the effect of exacerbating this increase (Fig. 2). Note the change in scale between graphs.
Figure 3 shows the time course of four first Principal Components 1. In each case they are also noted to be
rising strongly across time.
Supplementary Fig. 1 and Figs. 4 and 5 are paired scatterplot matrices showing the bivariate relationship of
the raw CAR’s, ETOPFACAR’s and cancer rates with substance exposures respectively. In Supplementary Fig. 1
the five chromosomal anomalies appear in the last five rows of the plot matrix and the cannabinoid exposures
appear in the middle columns. Cannabis exposure appears in the third column from the left. The relationship
between exposures to cannabis and cannabinoids is therefore seen in the positive slopes of the regression lines in
the intersection of these rows and columns. Figure 4 is very similar to this but uses the ETOPFA-adjusted data.
In this scatterplot matrix it is noted that the slopes of the regression lines in the corresponding plots is much
more steeply positive. The relationship of these CAR’s with cannabigerol is different in this plot matrix as most
anomalies have a negative relationship with cannabigerol exposure.
Figure 5 performs a similar function for the cancer data. In this plot matrix the cancers occupy the last five
rows. The slope of the regression lines for cannabis and the cannabinoids THC, cannabidiol, cannabichromene,
and cannabinol is strongly positive. In the case of cannabigerol the relationship is more heterogeneous.
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Figure 3.  The time course of the four PC1’s for: CAR, ETOPFACAR, cannabinoids and Cancer data (Created in
R-Studio version 1.3.1093 using ggplot2 version 3.3.2).
Supplementary Figs. 2–6 and 7–10 and Fig. 6 show the relationship between the pathologies of interest
and the various cannabinoids in more detail for CAR’s, ETOPFACAR’s and cancers respectively. These figures
make explicit the positive relationship between CAR’s and cancers and cannabis, THC, cannabinol, and cannabichromene (Supplementary Figs. 2–5) which is increased by ETOPFA correction (Fig. 6 and Supplementary
Figs. 7–9) whilst the relationship between these pathologies and cannabigerol is more complex (Supplementary
Figs. 6 and 10).
Supplementary Figs. 11 and 12 and Figs. 7 and 8 show Corrplot correlograms of the correlation coefficients and their significance for the CAR’s and ETOPFACAR’s and cancers respectively. In each case the congenital anomalies appear in the right hand columns along with their combined principal component which is
PC!DefxRaw in Supplementary Figs. 11 and 12 and PC1TrueDefx in Figs. 7 and 8. All four correlograms include
the PC1Cannabinoid for cannabinoids and PC1_5xCancers which combines the data for the five cancers. In each
case the cannabinoids occupy the middle rows.
Positive Pearson correlation coefficients are noted for the CAR’s (Supplementary Fig. 11) which are shown
in Supplementary Fig. 12 to be significant for Down syndrome but not for other CAR’s. ETOPFA adjustment
has little effect on these correlation coefficients (Fig. 7) and does not change the significance levels of the correlations appreciably (Fig. 8).
Supplementary Figs. 13–15 present time-based cannabis use quintile plots and boxplots for CAR’s, ETOPFACAR’s and cancers respectively. One reads the boxplots by noting where the notches do not overlap which
signifies statistically significant differences. The cannabis use quintile categories may be dichotomized as the
highest quintile against the lower four quintiles. In each case time-dependent dichotomization reveals very different trends for the highest and lower quintiles (Supplementary Figs. 13–15, panels C and D).
The statistics applicable to the continuous quintile data in these three domains are shown in Supplementary
Table 6. These results confirm formally the visual impressions from inspection of Supplementary Figs. 13–15
of important changes at higher quintiles of cannabinoid exposure with high levels of statistical significance
(CAR’s: β-est. = 1.76 (1.22, 2.29), P = 3.81 × 10–9; ETOPFACAR’s: β-est. = 1.59 (1.04, 2.14), P = 1.15 × 10–7; cancers:
β-est. = 0.43 (0.26, 0.61), P = 1.69 × 10–6).
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Figure 4.  Paired scatterplot matrix for the covariates in the ETOPFACAR dataset. (Created in R-Studio version
1.3.1093 using ggpairs function from the GGally package version 2.0.0).
The statistics for the categorical quintile data confirm the visual impressions of no significant differences
between quintiles on the Chi Squared test for trend (ChiSqu. = 444, 444, 3000, df = 440, 440, 2996, P = 0.44,
0.44, 0.48 respectively) but statistically significant differences on comparison of dichotomized data on testing
for Student’s T (CAR’s: t = 5.221, df = 16.583, P = 7.49 × 10–5; ETOPFACAR’s: t = 4.296, df = 16.08, P = 5.49 × 10–4,
cancers: t = 5.17, df = 251.52, P = 4.76 × 10–7).
Table 1 shows Cohen’s D which is a measure of effect size, its qualitative meaning, and applicable E-Values
and P-Values for various quintile dichotomizations. The effect sizes are noted to be large for the CAR’s and
ETOPFACAR’s for all comparisons and medium for the cancer comparisons between the third and fifth quintiles.
Supplementary Tables 7–9 show the results of inverse probability-weighted instrumental variable regression
against PC1 across the three domains in increasingly complex models. The first model shown in Supplementary Table 7 is a model additive for drugs. It is followed by a model interactive for drugs. The third and fourth
models are again additive and interactive respectively but substitute the cannabinoids THC, cannabigerol and
cannabichromene in place of cannabis. The fifth and sixth models are additive and interactive respectively and
include the PC1 of cannabinoids with all the covariates including six ethnicities and median household income.
All six models listed include cannabinoids with highly significant positive terms (from β-est. = 3.67 (2.77, 4.56),
P = 3.06 × 10–12) in model four) and in all six models the effect of cannabinoids is positive overall.
Supplementary Table 8 is structured similarly to Supplementary Table 7 but uses the ETOPFA-adjusted data
and includes an additive and an interactive comprehensive model with all covariates including ethnicity and
income and the three cannabinoids THC, cannabigerol and cannabichromene. Seven of the eight models listed
in this Table incorporate positive and highly significant terms including cannabinoids (from β-est. = 5.40 (3.79,
7.00), P = 2.16 × 10–9 in model six) and in six models the overall effect of cannabinoids is positive (models six
and eight being the exceptions).
Supplementary Table 9 is structured similarly to Supplementary Table 8 and in this Table the dependent
variable is the PC1 for the cancers. All eight final models include terms positive and significant for cannabinoids
(from β-est. = 14.84 (10.88, 18.79), P < 2.20 × 10–16 in model three; β-est. = 0.35 (0.29, 0.41), P < 2.20 × 10–16 in
model five; β-est. = 1.48 (1.19, 1.77), P < 2.20 × 10–16 in model seven) and in five models the overall effect of cannabinoids is positive (models two, four and eight being the exceptions).
Thus in all three instrumental variable regression tables Supplementary Tables 7–9 terms for cannabis, cannabinoids and PC1-cannabinoids are noted to be significant and positive.
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Figure 5.  Paired scatterplot matrix for the covariates in the cancer dataset. (Created in R-Studio version
1.3.1093 using ggpairs function from the GGally package version 2.0.0).
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Figure 7.  Correlogram drawn in Corrplot for the Pearson correlation coefficients between covariates for
ETOPFA-corrected data. The colouring is scaled from strongly positive (bright red) to strongly negative
(bright royal blue). The upper triangle represents these associations as ellipses where the width of the ellipses
in inversely proportional to the strength of the correlation so that the strongest associations have the narrowest
ellipses. Ellipses slope to the right for positive relationships and to the left for negative relationships. (Created in
R-Studio version 1.3.1093 using corrplot version 0.84).
Tables 2, 3, and 4 perform a similar function for inverse probability-weighted robust generalized regression
models across the three domains. Table 2 presents final inverse probability weighted robust generalized linear
regression models for the CAR dataset. Additive and interactive models for drugs, additive and interactive
models for drugs including cannabinoids and additive and comprehensive models including sociodemographic
and socioeconomic covariates are presented. Terms including cannabinoids are positive and highly significant in
five of the six final models shown and in the first, third, fourth and fifth models the effect of rising cannabinoid
exposure is positive overall.
Table 3 is set out like Table 2 but also includes additive and interactive comprehensive models for cannabinoids. Terms including cannabinoids are positive and very highly significant (from β-est. = 3.94 (2.62, 5.25),
P = 6.46 × 10–6 in model seven) in all eight models and in each case the overall effect of rising cannabinoid
exposure is positive overall.
Table 4 is structured similarly to Table 3. In each of the eight final robust models illustrated terms including
cannabinoids are positive and highly significant (from β-est. = 0.97 (0.75, 1.19), P = 5.15 × 10–11 in model seven)
and the overall effect of cannabinoids is positive in seven of the eight models (the exception being model eight).
Hence in these robust regression models many terms involving cannabinoids are again noted to be positive
and highly significant and the effects of cannabinoids are strongly positive across this model series overall.
Supplementary Table 10 and Table 5 list the E-Values which may be drawn from the linear and instrumental
variable regression model respectively. Minimum E-Values from linear models are noted to range from 1.21 to
11.25, with median, mode and interquartile ranges of 3.05, 3.44 (1.58, 5.86, Supplementary Table 10). Similar
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Figure 8.  Correlogram drawn in Corrplot for the significance of correlative relationships between covariates for
ETOPFA-corrected data. Numbers represent the P-values corresponding to the Pearson correlation coefficients.
The colouring is scaled from strongly positive (bright red) to strongly negative (bright royal blue). The upper
triangle represents these associations as ellipses where the width of the ellipses in inversely proportional to the
strength of the correlation so that the strongest associations have the narrowest ellipses. Ellipses slope to the
right for positive relationships and to the left for negative relationships. (Created in R-Studio version 1.3.1093
using corrplot version 0.84).
statistics for the minimum E-Values from the instrumental variable regression models are 10.96, 12.01 (2.23,
1250, Table 5) so that the minimum E-Values arising from the more sophisticated type of regression are significantly larger than those originating from simple linear regression (Wilcoxson’s W = 179.5, P = 0.0011).
56 minimal E-Values are listed in descending order in Supplementary Table 11 where 55 are noted to be
greater than 1.25, 29/56 (51.87%) exceed five and 21 are larger than 9.0. The mean, median and modal E-Values
for this series are 2.52 × 1016, 5.365 and 7.75 and the interquartile range is 2.17 to 44.16. The significance of these
values is that 1.25 is the generally accepted cut-off for causal effects71 and 9.0 is the applicable E-Value for the
tobacco-lung cancer relationship and is generally considered to be large72. Five is also considered to be a sizeable E-Value. Given that this is a comprehensive list of positive E-Values to emerge from these models this is an
impressive list of minimum E-Values.
Supplementary Figs. 16–18 show the time dependent and box plot aggregated charts across the three domains
by cannabis legal status. Strong effects are shown on dichotomization as indicated. Some of these are summarized
in Fig. 9.
Final models from the time-dependent analysis of these data as continuous variables are shown in Table 6.
Many highly significant effects shown including the effect of legal cannabis on the CAR data (β-est. = 2.57 (1.03,
4.11), P = 0.0014) and the effect of liberal as opposed to illegal cannabis regimes on cancer rates (β-est. = 0.58
(0.44, 0.72), P = 1.14 × 10–15).
As suggested by the dichotomous boxplots in these four figures these data can also be analyzed as categorical variables by dichotomous legal status. The CAR PC1 data may be dichotomized as illegal (-0.064 ± 0.114,
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Quintiles 3 v 5

Quintiles 4 v 5

Quintile 5 v lower

Cohen’s D
PC1 defects

2.51 (1.61, 3.42)

1.85 (1.05, 2.65)

1.78 (1.18, 2.37)

PC1 ETOPFA

2.09 (1.25, 2.93)

1.53 (0.77, 2.29)

1.57 (0.98, 2.16)

PC1 cancers

0.54 (0.23, 0.85)

0.16 (0.14, 0.47)

0.44 (0.26, 0.62)

Effect sizes
PC1 defects

Large

Large

Large

PC1 ETOPFA

Large

Large

Large

PC1 cancers

Medium

Negligible

Small

E-Values
PC1 defects

19.25, 11.25

10.21, 6.24

9.57, 6.652

PC1 ETOPFA

12.90, 7.75

7.52, 4.64

7.86, 5.43

PC1 cancers

2.91, 2.63

1.62, 1.38

2.68, 2.52

P-levels of T-tests
PC1 Defects

2.81E-06

4.13E-05

7.49E-05

PC1 ETOPFA

3.43E-05

4.45E-04

5.49E-04

PC1 Cancers

4.41E-04

0.2777

4.72E-06

Table 1.  Quintile analysis. Cohen’s D, Effect Sizes, E-Values and P-values for quintile analyses.

Parameter

Estimate (C.I.)

P-Value

Cannabis

1.56 (0.4, 2.72)

0.0071

Cigarettes

− 14.87 (− 19.87, − 9.87)

3.83E−06

AUD

74.69 (46.65, 102.74)

1.88E−05

Cigarettes: AUD

− 289.8 (− 428.68, − 150.92)

3.70E−04

CBG

1.42 (0.3, 2.55)

0.0203

Cigarettes

− 14.85 (− 19.8, − 9.89)

3.41E−06

4.49 (2.63, 6.36)

6.70E− 05

Drugs—additive model
svyglm(PC1 raw anomalies ~ cigarettes + AUD + mrjmon + Analgesics + cocaine + MHY)

Drugs—interactive model
svyglm(PC1 raw anomalies ~ cigarettes * AUD * mrjmon + analgesics + cocaine + MHY)

Cannabinoids—additive model
svyglm(PC1 raw anomalies ~ cigarettes + AUD + THC + CBG + CBC + analgesics + cocaine)

Cannabinoids—interactive model
svyglm(PC1 raw anomalies ~ cigarettes * AUD * THC * CBG * CBC + Analgesics + cocaine)
Cigarettes: CBG
Full additive model
svyglm(PC1 raw anomalies ~ cigarettes + AUD + PC1− Cannabinoids + analgesics + cocaine + income + 6_races)
AIAN

10.03 (5.3, 14.75)

0.0003

PC1-Cannabinoid

0.65 (0.2, 1.11)

0.0097

Cigarettes

− 14.12 (− 18.82, − 9.42)

3.82E−06

Full interactive model
svyglm(PC1 raw anomalies ~ cigarettes * AUD * PC1-cannabinoids + analgesics + cocaine + income + 6_races)
Cocaine

106.67 (24.71, 188.64)

0.0186

PC1-Cannabinoid

3.01 (0.47, 5.54)

0.0303

Cigarettes: AUD

320.87 (26.47, 615.27)

0.0446

AUD: PC1-Cannabinoid

− 34.59 (− 66.35, − 2.83)

0.0447

AUD

− 82.77 (− 148.26, − 17.29)

0.0218

Asian

− 23.31 (− 40.72, − 5.89)

0.0159

Cigarettes

− 35.71 (− 50.08, − 21.35)

8.11E−05

Table 2.  Robust IPW-weighted generalized regression analyses on PC1 for raw congenital anomaly data. Final
robust generalized linear regression models for CAR Dataset.
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Parameter

Estimate (C.I.)

P-Value

ETOPFA data
Drugs—additive model
svyglm(PC1_ETOPFA_anomalies ~ cigarettes + AUD + mrjmon + Analgesics + cocaine + MHY)
Cannabis

1.56 (0.51, 2.6)

0.0071

Cigarettes

− 13.19 (− 17.62, − 8.75)

3.83E−06

Drugs—interactive model
svyglm(PC1_ETOPFA_anomalies ~ cigarettes * AUD * mrjmon + Analgesics + cocaine + MHY)
AUD

98.08 (58.27, 137.89)

5.81E−05

AUD: Cannabis

21.02 (2.59, 39.44)

0.0345

Cigarettes: AUD

− 229.76 (− 329.02, − 130.5)

0.0001

Cannabinoids—additive model
svyglm(PC1_ETOPFA_anomalies ~ cigarettes + AUD + THCRt + CBGRt + CBCRt + analgesics + cocaine)
CBG

2.94 (1.39, 4.48)

0.0010

CBC

− 1.53 (− 2.67, − 0.39)

0.0146

Cigarettes

− 13 (− 17.52, − 8.48)

7.33E−06

Cannabinoids—interactive model
svyglm(PC1_ETOPFA_anomalies ~ cigarettes * aUD * THCRt * CBGRt * CBCRt + analgesics + cocaine)
Cigarettes: CBG

4.53 (2.67, 6.39)

6.70E−05

CBG

3.49 (0.44, 6.53)

0.0338

Cigarettes: THC: CBC

3.78 (0.23, 7.34)

0.0473

Full additive model
svyglm(PC1_ETOPFA_anomalies ~ cigarettes + AUD + PC1_Cannabinoids + analgesics + cocaine + income + 6_races)
PC1_Cannabinoid

0.64 (0.22, 1.06)

0.0063

Cigarettes

− 12.33 (− 16.59, − 8.07)

5.73E−06

Full interactive model
svyglm(PC1_ETOPFA_anomalies ~ cigarettes * AUD * PC1_cannabinoids + analgesics + cocaine + income + 6_races)
PC1_Cannabinoid

0.64 (0.22, 1.06)

0.0063

Cigarettes

− 12.33 (− 16.59, − 8.07)

5.73E−06

Cannabinoids full additive model
svyglm(PC1_ETOPFA_anomalies ~ cigarettes + THC + CBG + CBC + AUD + Analgesics + cocaine + income + 6_races)
CBG

3.94 (2.62, 5.25)

6.46E−06

AIAN

19.58 (12.65, 26.52)

1.46E−05

Cocaine

94.7 (12.92, 176.47)

0.03337

AUD

− 26.81 (− 45.85, − 7.78)

0.01141

CBC

− 2.8 (− 4.48, − 1.11)

0.00366

Cigarettes

− 11.53 (− 15.82, − 7.24)

2.79E−05

Cannabinoids full interactive model
svyglm(PC1_ETOPFA_anomalies ~ cigarettes * THC * CBG * CBC + AUD + Analgesics + cocaine + income + 6_races)
AIAN

11.36 (8.14, 14.58)

6.01E−07

CBG

3.8 (1.74, 5.86)

0.0015

Cocaine

78.22 (7.94, 148.49)

0.0401

Cigarettes: CBC

− 14.08 (− 24.26, − 3.9)

0.0128

Cigarettes

− 73.02 (− 115.67, − 30.38)

0.0029

Asian

− 19.81 (− 29.84, − 9.77)

0.0008

Table 3.  Robust IPW-weighted generalized regression analyses on PC1 for ETOPFA-adjusted congenital
anomaly data. Final robust generalized linear regression models for ETOPFACAR Dataset.

mean ± S.E.M.) compared to liberal (0.395 ± 0.206; t = 1.945, df = 70.588, P = 0.056) or not legal (0.078 ± 0.106)
compared to legal (2.509 ± 0.002; t = 22.76, df = 108.11, P = 9.67 × 10–43). The ETOPFACAR PC1 data may be
dichotomized as not legal (0.273 ± 0.106) compared to legal (2.546 ± 0.081; t = 17.01, df = 7.330, P = 3.71 × 10–7).
The cancer PC1 data may be dichotomized as illegal (− 0.277 ± 0.0.54) compared to liberal (0.189 ± 0.615; t = 5.703,
df = 476.848, P = 2.06 × 10–8).
These results confirm formally at both continuous and categorical analysis the strong visual impression from
inspection of Supplementary Figs. 16–18 and Fig. 9 that liberal cannabis regimes greatly exacerbate the rates of
CAR’s, ETOPFACAR’s and cancers studied at high levels of statistical significance.
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Parameter

Estimate (C.I.)

P-value

Cannabis

1.6 (1.08, 2.12)

2.67E−07

AUD

− 22.88 (− 32.34, − 13.42)

2.02E−05

Cigarettes

54.66 (26.52, 82.8)

0.0004

Cigarettes: Cannabis

15.56 (6.58, 24.55)

0.0015

AUD

48.5 (8.04, 88.96)

0.0233

Cigarettes: AUD: Cannabis

− 140.39 (− 258.36, − 22.41)

0.0243

Cigarettes: AUD

− 655.34 (− 1016.26, − 294.42)

0.0009

THC

2.4717 (1.81, 3.13)

2.23E−09

CBC

− 1.7349 (− 2.78, − 0.69)

0.0020

Cigarettes: THC: CBG: CBC

1.47 (0.9, 2.04)

7.84E−06

Cigarettes: CBG: CBC

9.18 (5.35, 13.01)

2.70E−05

Cigarettes: CBG

36.19 (20.55, 51.83)

4.56E−05

THC: CBG: CBC

− 0.17 (− 0.31, − 0.04)

0.0133

CBG

− 7.44 (− 11.98, − 2.9)

0.0025

CBG: CBC

− 1.74 (− 2.71, − 0.76)

0.0012

Drugs—additive model
svyglm(PC1-cancer ~ cigarettes + AUD + Cannabis + analgesics + cocaine + MHY)

Drugs—interactive model
svyglm(PC1-Cancer ~ cigarettes * AUD * cannabis + analgesics + cocaine + MHY)

Cannabinoids—additive model
svyglm(PC1-cancer ~ cigarettes + AUD + THC + CBG + CBC + Analgesics + cocaine)

Cannabinoids—interactive model
svyglm(PC1-cancer ~ cigarettes * AUD * THC * CBG * CBC + Analgesics + cocaine)

Full additive model
svyglm(PC1-cancer ~ cigarettes + AUD + PC1-Cannabinoids + analgesics + cocaine + income + 6_races)
Asian

10.72 (8, 13.44)

9.88E−10

African

0.46 (0.32, 0.59)

2.64E−08

PC1-Cannabinoid

0.37 (0.25, 0.48)

1.32E−07

Caucasian

5.38 (3.31, 7.45)

6.89E−06

Hispanic

0.36 (0.17, 0.55)

0.0005

Full Interactive Model
svyglm(PC1-cancer ~ cigarettes * AUD * PC1-cannabinoids + analgesics + cocaine + income + 6_races)
Asian

10.24 (7.77, 12.71)

3.15E−10

African

0.48 (0.35, 0.6)

2.73E−09

Caucasian

4.86 (3.06, 6.66)

3.99E−06

Cigarettes: PC1-Cannabinoid

5.38 (3.01, 7.74)

5.85E−05

Hispanic

0.29 (0.11, 0.46)

0.0024

PC1-Cannabinoid

− 0.79 (− 1.31, − 0.27)

0.0050

Cannabinoids full additive model
svyglm(PC1-cancer ~ cigarettes + THC + CBG + CBC + AUD + Analgesics + cocaine + income + 6_races)
THC

0.97 (0.75, 1.19)

5.15E−11

Asian

9.2 (6.75, 11.65)

3.46E−09

African

0.41 (0.28, 0.53)

5.71E−08

Caucasian

4.32 (2.43, 6.22)

5.35E−05

Hispanic

0.28 (0.09, 0.46)

0.0051

Cannabinoids full interactive model
svyglm(PC1-cancer ~ cigarettes * THC * CBG * CBC + AUD + Analgesics + cocaine + income + 6_races)
Asian

7.31 (5.31, 9.31)

1.52E−08

African

0.37 (0.26, 0.48)

8.87E−08

THC: CBG: CBC

4.93 (2.83, 7.03)

4.67E−05

THC

70.96 (40.45, 101.47)

5.22E−05

Caucasian

2.79 (1.51, 4.06)

0.0001

THC: CBG

21.27 (11.19, 31.35)

0.0002

THC: CBC

16.76 (7.95, 25.57)

0.0006

Cigarettes: THC: CBC

− 89.35 (− 126.43, − 52.27)

3.14E−05

Cigarettes: THC: CBG

− 115.05 (− 161.96, − 68.14)

2.42E−05
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Parameter

Estimate (C.I.)

P-value

Cigarettes: THC: CBG: CBC

− 26.26 (− 36.06, − 16.46)

6.06E−06

Cigarettes: THC

− 380.98 (− 519.06, − 242.9)

3.69E−06

Table 4.  Robust IPW-weighted generalized regression analyses on PC1 for selected cancer incidence data.
Final robust generalized linear regression models for cancer Dataset.

Supplementary Table 12 shows Cohen’s D as an effect size measure, the qualitative characterizations of Cohen’s
D, and the applicable E-Values and P-Values for legal status metrics. The strong effects noted in the preceding
graphs are confirmed here on quantitative analysis as both effect sizes and minimum E-Values.

Discussion

The present study examined the bivariate and multivariate relationships of the principal components of five
chromosomal pathologies (trisomies 13, 18, 21, the monosomy Turner syndrome and Deletion 22q11.2) and five
cancers (thyroid, liver, breast and pancreatic cancer and acute myeloid leukaemia) to substance exposure, income
and ethnicity covariates in a quantitative causal analysis framework. The main results of the present study were
that all ten pathologies examined are rising both across time and in relation to the five cannabinoids examined
[cannabis, THC, cannabinol (CBN), cannabichromene (CBC) and cannabigerol (CBG)] in a manner which was
robust to adjustment in multivariable inverse probability weighted instrumental variable and robust generalized
regression models. Cannabis and all four cannabinoids were significantly related to the PC1’s for chromosomal
anomaly rates both before and after adjustment for ETOPFA’s and to the cancer PC1 in final regression models
after full adjustment for sociodemographic factors. Large effect sizes were demonstrated for both congenital
anomaly PC’s between the highest quintile of cannabis use and the third and fourth quintiles and a medium
effect size was shown for the cancer PC. Large effect sizes were also demonstrated between states with legal and
not legal cannabis legal regimes for chromosomal anomaly PC’s and a medium effect size was demonstrated
between illegal and liberal legal paradigms for the cancer PC1. These effect sizes were accompanied by appropriately large minimal E-values of greater than five and 2.4 respectively, and small P-values (P = 9.67 × 10–43 and
P = 2.66 × 10–15 respectively).
Previous studies have reported individual conditions in the young known to be associated with cannabisrelated chromosomal damage: current data highlight cannabis damage on multiple human chromosomes. Liveborn congenital anomaly rates are known to underestimate true rates due to both spontaneous and induced
abortion of damaged foetuses. The existence of an experimentally well described threshold dose in the micromolar range73–81 explains both why inherited morbidity is not observed more commonly at present after prenatal exposure and why rates jump abruptly with the increased use, availability and concentration implicit
under the legalization paradigm as shown clearly by epidemiological data from Colorado, Canada, Hawaii and
Australia8,10,37,82,83.
It is intriguing to note the variety of chromosomal-toxic mechanisms which are implied by the present results.
Whereas the trisomy/monosomy (Turner) syndromes are presumably related to chromosomal mis-segregation
errors4, horizontal transversions and gene amplifications on chromosome 12 in testicular cancer43–46,84,85 and
deletion of the short arm of chromosome 22 in Deletion 22q11.2 signify multiple pathways to major chromosomal pathology.
This report studied five congenital chromosomal anomalies and five cancers. Dose–response effects were
noted for many associations which were independently significant for cannabis, THC, cannabichromene and
cannabigerol and these relationships were preserved after adjustment for estimated ETOPFA rates which is a
preponderant effect especially for chromosomal anomalies which are terminated prior to birth at high rates.
All ten disorders were noted to rise strongly over time and in relationship to cannabis and the cannabinoids
THC, cannabigerol, cannabinol and cannabichromene. Strong effects by quintile of cannabis exposure were
noted which were also reflected in the impact of cannabis legal status. Many effect sizes were noted to be strong
with many Cohen’s D’s above 1.4, where relationships above 0.8 being typically described as being strong86. The
pooled disorder-cannabinoid relationship satisfied formal criteria of causality as assessed by inverse probability
weighting of robust marginal structural models with P-values significant from 2.8 × 10–7 and 55/56 e-Values
being greater than 1.25 which is the causal threshold and 30/56 minimum e-Values being greater than 5 which is
relatively large. The individual disorders are also the subject of separate space–time and causal inference analyses
which are presently being prepared.
The findings are prominent for showing a dramatic rise from the fourth to the fifth quintile of cannabis use
and a reflection of a similar kind when considering the cannabis legal paradigm. This is reminiscent of a similar
finding for 34 defects recently published which also showed a major jump from the fourth to fifth q
 uintile39.
This is concerning because it directly reflects the well described exponential dose response which has been
found in many cannabinoid genotoxicity studies and in many studies of the pharmacology of cannabinoids
generally14,26,59–61.
A direct corollary of this bench to bedside parallelism is that as the community moves steadily into higher
echelons of cannabis use the genotoxic sequelae will be unprecedentedly magnified—in coming generations. It is
this multi-generational and transgenerational aspect of cannabinoid genotoxicity which is of particular concern
in the context of disproportionate dose-exposure escalation.
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Parameter

Estimate (C.I.)

E-Value

1.17 (0.3, 2.04)

5.02, 1.93

Cigarettes: Cannabis

19.28 (13.34, 25.21)

2.09E + 08, 7.18E + 04

AUD: Cannabis

69.54 (42.68, 96.4)

1.71E + 29, 1.20E + 18

0.95 (0.3, 1.6)

4.04, 1.94

3.67 (2.77, 4.56)

48.91, 22.14

0.6 (0.33, 0.87)

3.03, 2.12

4.37 (2.97, 5.77)

213.43, 47.55

1.29 (0.4, 2.17)

5.51, 2.17

73.95 (48.33, 99.57)

2.13E + 26, 2.14E + 17

3.14 (1.74, 4.54)

37.77, 9.79

Cigarettes: CBC

2.31 (1.5, 3.11)

17.25, 7.75

CBG

7.38 (4.18, 10.57)

2.16E + 03, 105.18

CBG: CBC

0.98 (0.49, 1.47)

4.51, 2.57

0.68 (0.39, 0.97)

3.15, 2.23

5.4 (3.79, 7)

595.814, 109.21

4.21 (2.91, 5.5)

176.69, 44.16

0.45 (0.2, 0.69)

2.83, 1.87

14.84 (10.88, 18.79)

2.82E + 07, 3.53E + 05

1.98 (1.61, 2.36)

18.58, 12.01

CBC

12.78 (6.96, 18.59)

1.53E + 07, 1.14E + 04

THC: CBC

3.02 (1.33, 4.71)

84.47, 9.91

THC: CBG: CBC

0.6 (0.17, 1.04)

3.63, 1.76

CBG

7.27 (0.46, 14.09)

1.66E + 04, 2.99

CBG: CBC

1.79 (0.1, 3.49)

18.01, 1.53

0.35 (0.29, 0.41)

2.51, 2.25

6.63 (4.8, 8.46)

1.45E + 04, 1.25E + 03

1.48 (1.19, 1.77)

14.18, 9.43

CBG

10.6 (4.39, 16.81)

7.52E + 06, 1.08E + 03

THC: CBG: CBC

3.81 (1.54, 6.08)

4159.71, 17.54

CBG: CBC

2.47 (0.93, 4)

67.03, 7.00

THC: CBG

16.09 (5.82, 26.36)

1.89E + 10, 9.37E + 03

CBC

7.52 (2.44, 12.59)

9.16E + 05, 65.62

RAW RATES
Drugs—additive model
Cannabis
Drugs—interactive model

Cannabinoids—additive model
CBG
Cannabinoids—interactive model
Cigarettes: CBG
Full additive model
PC1-Cannabinoids
Full interactive model
PC1-Cannabinoids
ETOPFA DATA
Drugs—additive model
Cannabis
Drugs—interactive model
Cigarettes: AUD: Cannabis
Cannabinoids—additive model
CBG
Cannabinoids—interactive model

Full additive model
PC1-Cannabinoids
Full interactive model
PC1-Cannabinoids
Cannabinoid Full Additive Model
CBG
CANCER DATA
Drugs—additive model
Cannabis
Drugs—interactive model
Cigarettes: Cannabis
Cannabinoids—additive model
THC
Cannabinoids—interactive model

Full additive model
PC1-Cannabinoid
Full interactive model
Cigarettes: PC1-Cannabinoid
Full additive model with cannabinoids
THC
Full interactive model with cannabinoids

Continued
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Parameter

Estimate (C.I.)

E-Value

THC

46.13 (11.12, 81.15)

8.05E + 28, 1.73E + 07

THC: CBC

11.15 (0.87, 21.42)

1.63E + 07, 6.57

Table 5.  E-values of instrumental variable regression models. E-Values from instrumental variable regression
models.

ETOPFA − PC1 Over Time by Dichotomized Status

PC1 Cancer Over Time by Dichotomized Status

Data: SEER, CDC and RDAS, SAMHDA, NSDUH, SAMHSA

Data: SEER, CDC and RDAS, SAMHDA, NSDUH, SAMHSA
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Figure 9.  Effect of dichotomized cannabis legal status on PC1 for ETOPFA-corrected and cancer data. (A)
Scatterplot over time for PC1 for ETOPFA-corrected anomalies for legal status dichotomized as legal cannabis
states v not legal cannabis states. (B) Scatterplot over time for PC1 for cancer incidence dichotomized by legal
status as illegal states v. liberal states. (C) Boxplot for PC1 for ETOPFA-adjusted congenital anomalies timeaggregated data by legal status dichotomized as in (A). (D) Boxplot for PC1 for selected cancer incidence of
dichotomized legal status over aggregated time dichotomized as in (B). (Created in R-Studio version 1.3.1093
using ggplot2 version 3.3.2).
Cannabis use amongst young adults has been unanimously linked in four of four studies with the subsequent
development of testicular c ancer43–46. Testicular cancer is interesting in that 90% of cases involve the formation
of an isochromosome 12, and in the remainder an internal intra-chromosomal amplification of parts of the
long arm of chromosome 12 occurs so that the relative gene dosage is increased under both s cenarios40. Cannabis exposure—testicular oncogenesis dose–response effects have been described in several epidemiological
series43–45. Testicular cancer is believed to arise from pro-oncogenic germ stem cell mutations which occur during in utero life which are subsequently activated by the hormonal surge of pubertal development40–42. In the
case of this tumour therefore cannabis accelerates the subclinical pro-oncogenic phase from several decades to
just a few years.
Most particularly, the present demonstration of cannabinoid-linked genotoxicity applying to over 500 MB of
the human genome accommodated on chromosomes 12, 13, 18, 21 and X clearly indicates that mechanisms exist
in man linking in vitro genotoxic effects to clinical effects. Hence it becomes plausible to link the 21 congenital
defects noted in Hawaii with cannabis-only e xposure37, the 13 congenital anomalies noted in A
 ustralia38, limb
87,88
defects noted in France and G
 ermany , 29% increase in total congenital anomalies listed in C
 olorado8 a tripling of total birth defects in the high-cannabis using areas of C
 anada10 and 34 congenital anomalies in U
 SA39
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Parameters

Model parameters

Parameter

Estimate (C.I.)

P-value

R-Squared

0.0968

Wald ChiSqu

dF

P

4.93

3107

0.0030

Congenital anomaly raw data
lm(PC1DefectRaw ~ status)
Medical

0.11 (− 0.41, 0.64)

0.6720

Decriminalized

0.62 (0.08, 1.16)

0.0263

Legal

2.57 (1.03, 4.11)

0.0014

0.46 (0.03, 0.89)

0.0388

0.0298

4.375

1109

0.0388

2.43 (0.88, 3.98)

0.0027

0.0711

9.425

1109

0.0027

0.0822

4.283

3107

0.0067

0.0403

0.0292

4.305

1109

0.0404

0.0048

0.0620

8.272

1109

0.0048

0.0801

22.73

3746

4.31E−14

lm(PC1DefectRaw ~ dichotomized status)
Liberal (v Illegal)
lm(PC1DefectRaw ~ dichotomized status)
Legal (v Not Legal)

Congenital anomaly ETOPFA-adjusted data
lm(PC1_ETOPFA_adjusted ~ status)
Medical

0.16 (− 0.37, 0.68)

0.5643

Decriminalized

0.58 (0.04, 1.11)

0.0385

Legal

2.42 (0.87, 3.96)

0.0027

lm(PC1_ETOPFA_adjusted ~ dichotomized status)
Liberal (v Illegal)

0.45 (0.03, 0.88)

lm(PC1_ETOPFA_adjusted ~ dichotomized status)
Legal (v not legal)

2.27 (0.72, 3.82)

Cancer data
lm(PC1_cancer ~ status)
Medical

0.62 (0.44, 0.8)

1.84E−11

Decriminalized

0.52 (0.33, 0.7)

3.61E−08

Legal

0.69 (0.32, 1.05)

0.00026

0.58 (0.44, 0.72)

1.14E−15

0.081

67.05

1748

1.14E−15

0.45 (0.08, 0.83)

0.0182

0.0061

5.6

1748

0.0182

lm(PC1_cancer ~ dichotomized status)
Liberal (v Illegal)
lm(PC1_cancer ~ dichotomized status)
Legal (v Not Legal)

Table 6.  Effects of legal status. Final linear regression models for the effects of cannabis legal status in CAR,
ETOPFACAR and cancer datasets.

to transgenerational cannabinoid-induced genotoxic mechanisms. Evidence presented herein also implicates the
PC1 of five cancers seen clinically including acute myeloid leukaemia which has been previously d
 ocumented89,90
and breast cancer which is the most common cancer of all across USA with 279,100 cases expected in 2 02091.
Cannabis has previously been linked with both the induction and promotion of liver fibrosis and c irrhosis92,93
and with hepatic neocarcinogenesis by numerous mechanisms94. It has not been previously linked with the other
cancers studied to our knowledge.
Central to any discussion of genotoxic mechanisms of cannabis are considerations of the biological mechanisms by which it mediates chromosomal derangements and disruptions. Cannabis and the cannabinoids THC,
cannabinol, cannabidiol and cannabinol have been shown to be toxic to o
 ocytes6, sperm24,95,96, chromosomes96,
the bases of D
 NA97 and epigenetic regulation both by DNA m
 ethylation4,19,20,22–24,98 and histone f ormation16,99.
Cannabidiol and cannabidivarin in low doses have been shown to directly oxidize DNA bases which is a highly
oncogenic and mutagenic action97. Cannabinoids have long been recognized to reduce the synthesis of major
macromolecules of life including DNA, RNA proteins and histones13,18,60,99–104. Reduction in the linker histone
H1 has recently been shown to comprise a major oncogenic mechanism by making genes more accessible for
transcription105. One of the proteins whose synthesis is impeded is tubulin4,16. Tubulin polymerization has many
key roles in side the cell including the formation of the microtubules of the mitotic spindle and the molecular
skeleton of axons, cilia, centrosomes and flagella106. Deranged microtubular function has been linked with chromosomes sliding off the mitotic spindle in anaphase and the formation of micronuclei4,6,7,107 which are described
as being a major generator of the genetic chaos of c ancer4,107–118. Indeed, just as histones undergo post-translational modifications tubulin has also been shown to undergo post-translational modifications which target the
tubulin monomers for different subcellular destinations105. Errors in this “tubulin code” have been linked to disorders of flagellar function so that sperm are not able to swim normally in a linear trajectory and go round in circles
and fail to correctly target oocytes which is believed to be a potentially significant cause of male infertility105.
Hence whilst for descriptive purposes it is useful to describe cannabinoid-related molecular aberrations in various stratified layers and subcellular compartments, it seems likely that in reality the various layers are intimately
crosslinked and molecularly i nterdependent53,54,119–121. Unfortunately space precludes a more detailed discussion
in this forum but many of the important issues have been addressed elsewhere4,8–12,14,15,19,20,23,24,38,39,61,102,122,123.
We feel that our results are widely generalizable for several reasons. The cannabinoid-genotoxicity relationship fulfils most of the Hill criteria for causality including of strength of association, consistency among studies,
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specificity, temporality, coherence with known data, biological plausibility, dose–response relationship, analogy
with situations internationally and a rich experimental research b
 ase124. Naturally further details will be provided
in manuscripts addressing each of these issues individually including consideration in the native space–time data
context and formal causal inferential analyses. As noted many of the above findings have been replicated several
times elsewhere particularly with relation to the congenital chromosomal a nomalies8,10,37,38. These results are
based on the best data available globally. Since causal relationships were demonstrated herein we would expect
these relationships to be maintained wherever adequate data quality allows their assessment.
The techniques of causal inference are well satisfied by these results. For comparison, one notes that the
E-Value, or Expected value for the tobacco-lung cancer association is 9.0. As noted 21/56 (37.5%) of the E-Values
reported herein are above this cut-off and 29/56 (51.87%) exceed 5 which is also a sizeable E-Value.
The E-Value is the value of association required of some extraneous hypothetical unmeasured confounder
covariate with both the exposure of concern and the outcome of interest to explain away the observed results.
With such high results as are reported in our present paper such a confounder seems most unlikely. Inverse
probability weighting is the technique of choice to correctly weight an observational study and turn it into a
pseudo-randomized study from which causal inferences can appropriately be drawn. The classic concern with
observational studies is that one is in actually comparing “apples with oranges”. The use of inverse probability
weighting ensures that everything is “apples” as it were. It is therefore important to appreciate that, although it is
true that our study uses several multiple regression techniques, the extensive use of the techniques of quantitative
causal inference particularly inverse probability weighting and E-values are the appropriate tools with which to
address causal relationships and formally draw causal inferences.
Our study has many strengths including the use of advanced statistical techniques and the formal techniques
of causal inference. Its limitations include that we have not had space here to address each disorder separately
as those analyses are destined for other manuscripts. In common with all epidemiological studies we do not
have individual patient-level data available to us. It is also relevant to observe that the quantitative criteria
fulfilled by the analytical procedures in this study are those of causal inference in epidemiology and are widely
acknowledged in the discipline. However this is not the same thing as the formal assessment of causality as is
done in the controlled experimental laboratory setting, however given that it is not expected to ever be ethical
to conduct clinical trials of prenatal exposures these various analytical procedures are the next best thing which
can be achieved in clinical populations. Having said that we heartily endorse ongoing research into the many
mechanisms of cannabinoid genotoxicity for the same reason that the mechanisms of action of thalidomide
continue to be investigated experimentally to better understand its pathophysiology, to remediate its damage,
and to develop new lead compounds for novel clinical applications in cancer medicine and elsewhere. As patients
can be confused about the impact of early gestational cannabis exposure on developing pregnancies we advocate
for the development of a reliable biomarker to quantitate exposure and denominate future studies11.
Some of the statistical techniques used herein also have theoretical limitations. For example it has been noted
that inverse probability weighting cannot be used if all the subjects of a certain class at any time during the study
must receive a certain exposure c ondition125. Inverse probability weighting has also been observed not to work
well with small samples126. And its use for dealing with missing data also has methodological weaknesses127.
However these conditions were not observed in the present dataset and inverse probability was not used to
address missing data in these analyses. The interpretation of E-Values is necessarily always subjective and relies
on some background knowledge of the subject. For example if an E-Value is reported as five then the judgement
must be made as to whether confounding variables are likely to exist which correlate with both the exposure of
interest and the outcome of concern of the calculated magnitude to explain away an apparently causal effect. In
the present study with median and modal minimum E-Values of 5.65 and 7.75 this seems quite unlikely. Whilst
the use of principal components is a common analytical device it can never substitute for detailed investigations
of each identified syndrome separately and in detail. For this reason detailed causal modelling and spatiotemporal
analyses are indicated on each of the pathologies identified to further investigate the effects reported herein in
aggregate.
This report is intended as an introductory overview only and serves the purpose of introducing the subject
to readers’ consideration and detailed geospatial and causal inference studies of many congenital anomalies
and cancers are indicated to further explore these findings, issues which are indeed the subject of other recent
papers4,8,10,52,82,83,128–133 and current manuscripts. In conclusion this study of recent US data not only confirms
previous findings linking cannabis use with congenital and chromosomal anomalies, but it shows that those
impacts are significant at the public health level, likely account for much of their recent rise, explain the worrisome discontinuity and jump from the fourth to the fifth quintiles for cannabis exposure and are consistent
both with a rich experimental database and experience from other countries8,10,37,38. Since findings implicate over
500 MB of the human genome this directly explains the association of cannabis use with many other congenital
anomalies and heritable carcinogenesis previously reported. In the context of an exponential dose–response
curve for metabolically-genotoxically- and epigenetically-mediated cannabinoid-induced g enotoxicity14,26,59–61
the rising level of cannabis use induced by cannabis legalization and its severe sequaelae would appear to be
more than sufficient contraindication to continued relaxation of the laws surrounding cannabis, risks further
compounded by increasingly described heritable n
 eurotoxicity128,132,134–139.

Methods

Data. Data on US birth defect rates was downloaded from the National Birth Defect Prevention Network
(NBDPN) from CDC Atlanta Georgia website annual r eports63. Estimated early termination of pregnancy for
anomaly (ETOPFA) rates by birth defect type were taken as an average of a composite score from several Australian and USA published series shown as Supplementary Table 1364–66. The rate of change over time of these
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ETOPFA rates was taken from the only longitudinal annual series of ETOPFA rates which could be identified
which was the Western Australian series for Down syndrome (Supplementary Table 14140).
Age-adjusted state cancer data was taken from the National Program of Cancer Registries (NPCR) and
Surveillance Epidemiology and End Results (SEER) Incidence dataset US Cancer Statistics Public Use Database
2019 submission (2001–2017)62.
Drug use data by state was taken from the Restricted Data Analysis System (RDAS) from the annual National
Survey of Drug Use and Health (NSDUH) of the Substance Abuse and Mental Health Data Archive (SAMHDA)
from Substance Abuse and Mental Health Services Administration (SAMHSA)67. Intensity of cannabis use data
by ethnicity was taken from the RDAS, NSDUH at SAMHDA. Concentration of various cannabinoids nationally
was taken from published reports from the Drug Enforcement Agency (DEA)68–70. Median household income
data was downloaded from the US Census Bureau using tidycensus package in R
 141. Cannabis legal status in each
state was taken from an Internet search142.

Derived data. Intensity of ethnic-specific cannabis use was multiplied by state monthly cannabis use and

the THC concentration in Federal seizures to derive an estimate of ethnic THC exposure at state level. Quintiles
of cannabis use were derived by dividing the states for each year into five groups for cannabis use with details
as shown in Supplementary Table 15. State-based cannabinoid exposure was calculated by multiplying the state
levels of monthly cannabis use by the applicable cannabinoid concentration in Federal seizures. Chromosomal
anomalies are extensively screened for prenatally and subject to high rates of early termination of pregnancy for
anomaly (ETOPFA). Accordingly ETOPFA-corrected congenital anomaly rates were calculated by dividing the
observed anomaly rate in any year by the composite ETOPFA rate for that anomaly multiplied by the fraction of
ETOPFA for that year obtained from the Western Australian longitudinal series.

Statistics. Data was processed using R version 4.0.2 and R-Studio 1.3.1093 in October 2020. Data are listed
as mean ± standard error of the mean (S.E.M.). Data was manipulated using dplyr and graphs were drawn using
ggplot2, both from the tidyverse suite143. Correlograms were drawn using the packages corrplot and corrgram
from R144,145. Linear regression was performed using R-Base. Two-step instrumental variable regression was performed using package A
 ER146. Robust inverse probability weighted regression was performed using the survey
147
package with State as the identifying variable. In all cases initial models were serially reduced manually by the
deletion of the least significant term by the classical technique. The overall direction of models with rising cannabinoid exposure was determined by matrix multiplication with other covariates held constant at their means.
Effect size was quantitated using Cohen’s D from the effsize package86. Principal Components (PC’s) were calculated using the psych package and the number of PC’s required was determined formally using a Scree plot and
factor analysis148. Inverse probability weights were calculated using the ipw package149. E-Values were calculated
using the E-Value package149. T-tests were two-tailed. P < 0.05 was considered significant throughout.
Ethics. The Human Research Ethics Committee of the University of Western Australia approved this study
on 7th January 2020 RA/4/20/7724.

Data availability

Raw data including the software computing script accompanying this article have been made available online in
the Mendeley data repository and may be found at https://doi.org/10.17632/xwrkp6kjd9.1.
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